logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Is There a Possible Comeback for Nektar Therapeutics?

Nektar Therapeutics YoYoing Stock Price Investors who exaggerate their enthusiasm, or their apathy, towards buying and selling biotechnology stocks have sent the Nektar Therapeutics ( NKTR ) stock price to the Moon but wasted no time bringing it back to...

Read More

February 18, 2021

0

AstraZeneca and Amgen Product Tezepelumab Seems to Overcome the Resistance of Severe Asthma to Current Treatments

AstraZeneca and Amgen Announced Results for Tezepelumab for Severe Asthma Tezepelumab Reduced Exacerbations by 77% in Subgroup of Patients with Elevated Inflammatory Biomarkers in NAVIGATOR  Tezepelumab Reduced Exacerbations Requiring Hospitalization by 85% AstraZeneca ( AZN ) and Amgen ( AMGN )...

Read More

May 14, 2021

0

More Vaccines from GlaxoSmithKline: One with Sanofi and Another with CureVac

Sanofi and GlaxoSmithKline COVID-19 Vaccine Sanofi ( SNY ) and GlaxoSmithKline ( GSK ) COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in the Phase 2 trial.  Sanofi's and GlaxoSmithKline's adjuvanted recombinant COVID-19 vaccine candidate achieved...

Read More

May 17, 2021

0

Regeneron Pharmaceuticals: Good News During Bad Market Days

The market is sinking in a furious mood caused by the failure to figure out the pathway of criteria, which is currently controlling the stocks’ volatile performances. Today we are posting good news coming from a few biotech companies with...

Read More

February 23, 2021

0

Compugen: Good News During Bad Market Days

The market is sinking in a furious mood caused by the failure to figure out the pathway of criteria, which is currently controlling the stocks’ volatile performances. Today we are posting good news coming from a few biotech companies with...

Read More

February 23, 2021

0

Exelixis Has Good News for Metastatic Castration-Resistant Prostate Cancer

Exelixis Announced Results from its CABOMETYX® Combination with Roche's TECENTRIQ® News announced by Exelixis ( EXEL ) about encouraging results from the combination of its product cabozantinib ( CABOMETYX® ) with Roche’s product atezolizumab ( TECENTRIQ® ) on metastatic castration-resistant...

Read More

February 11, 2020

0

Recursion Pharmaceuticals: A Step Forward Towards Improving C. Difficile Treatment

Recursion Pharmaceuticals Product REC-163964 Recursion Pharmaceuticals Inc ( RXRX ) announced the initiation of an investigational new drug (IND)-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurrent Clostridium difficile (C. difficile) infections and potential...

Read More

May 25, 2021

0

The QIAGEN and Inovio Pharmaceuticals Partnership Extension  

QIAGEN and Inovio Pharmaceuticals Partnership QIAGEN ( QGEN ) and Inovio Pharmaceuticals ( INO ) announced an extension of their partnership. The extension comprises a new agreement for the development of liquid biopsy-based companion diagnostic products. These products are made...

Read More

February 25, 2021

0

Aptevo Therapeutics Inc Product APVO436 Improves the Treatment of Resistant AML and MDS

Aptevo Therapeutics Inc in the News Aptevo Therapeutics Inc ( APVO ) has positive results from the Phase 1 dose-escalation trial evaluating its lead ADAPTIR candidate product APVO436 for the treatment of acute myeloid leukemia ( AML ) and myelodysplastic...

Read More

May 26, 2021

0

The Johnson & Johnson COVID-19 Vaccine: Helping to Increase the Pressure on the Virus

Johnson & Johnson Receives an EUA from the U.S. FDA We appreciate the U.S. Food and Drug Administration's emergency use authorization ( EUA ) for the third vaccine for the prevention of SARS-CoV-2 (the virus that causes COVID-19). Three vaccines...

Read More

March 1, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 18
  • 19
  • 20
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy